CN116814501A - Bifidobacterium longum subspecies capable of relieving obesity and application thereof - Google Patents
Bifidobacterium longum subspecies capable of relieving obesity and application thereof Download PDFInfo
- Publication number
- CN116814501A CN116814501A CN202310873429.0A CN202310873429A CN116814501A CN 116814501 A CN116814501 A CN 116814501A CN 202310873429 A CN202310873429 A CN 202310873429A CN 116814501 A CN116814501 A CN 116814501A
- Authority
- CN
- China
- Prior art keywords
- strain
- longum
- bifidobacterium longum
- probiotic
- subspecies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000008589 Obesity Diseases 0.000 title claims abstract description 47
- 235000020824 obesity Nutrition 0.000 title claims abstract description 47
- 241001608472 Bifidobacterium longum Species 0.000 title claims abstract description 44
- 229940009291 bifidobacterium longum Drugs 0.000 title claims abstract description 44
- 241000185999 Bifidobacterium longum subsp. longum Species 0.000 claims abstract description 16
- 210000004185 liver Anatomy 0.000 claims abstract description 15
- 210000004369 blood Anatomy 0.000 claims abstract description 12
- 239000008280 blood Substances 0.000 claims abstract description 12
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 11
- 150000002632 lipids Chemical class 0.000 claims abstract description 8
- 239000006041 probiotic Substances 0.000 claims description 33
- 235000018291 probiotics Nutrition 0.000 claims description 33
- 230000000529 probiotic effect Effects 0.000 claims description 28
- 239000001963 growth medium Substances 0.000 claims description 20
- 238000004321 preservation Methods 0.000 claims description 13
- 244000199866 Lactobacillus casei Species 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 235000013406 prebiotics Nutrition 0.000 claims description 3
- 239000003223 protective agent Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 13
- 244000052616 bacterial pathogen Species 0.000 abstract description 7
- 230000021164 cell adhesion Effects 0.000 abstract description 5
- 230000007613 environmental effect Effects 0.000 abstract description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000009278 visceral effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 39
- 230000001580 bacterial effect Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 210000000577 adipose tissue Anatomy 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000009630 liquid culture Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 235000009200 high fat diet Nutrition 0.000 description 5
- 238000013116 obese mouse model Methods 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000015278 beef Nutrition 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 241000193171 Clostridium butyricum Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 240000006024 Lactobacillus plantarum Species 0.000 description 3
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229940072205 lactobacillus plantarum Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000004201 L-cysteine Substances 0.000 description 2
- 235000013878 L-cysteine Nutrition 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001495180 Arthrospira Species 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000222355 Trametes versicolor Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 235000019680 high-energy food Nutrition 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 101150099542 tuf gene Proteins 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Abstract
The invention relates to a bifidobacterium longum subspecies longum for relieving obesity and application thereof, wherein the bifidobacterium subspecies longum Bifidobacterium longum subsp.longum BL36 strain for relieving obesity is named as CGMCC No.24413. The strain has good gastrointestinal tract environmental tolerance, pathogenic bacteria inhibiting ability and cell adhesion ability, and can relieve obesity, reduce blood lipid level, reduce visceral index and reduce triglyceride level in liver.
Description
Technical Field
The invention belongs to the technical field of probiotics, relates to bifidobacterium longum subspecies for relieving obesity and application thereof, and in particular relates to a bifidobacterium subspecies Bifidobacterium longum subsp.longum BL36 strain, a culture containing the same, a probiotic containing the same, and application of the probiotic in preparation of products for preventing, relieving or treating obesity.
Background
With the continuous improvement of economic conditions and the continuous improvement of living standard, obesity is becoming one of the important factors for dangerous physical health. Obesity occurs because of an imbalance of energy, and either an increase in energy intake or a decrease in energy expenditure results in obesity. The excess energy is converted into white adipose tissue for storage. Obesity and chronic metabolic related diseases such as fatty liver, hyperlipidemia, type II diabetes and the like caused by obesity have higher incidence, and the diseases plagues people and become the world-focused problems. Long-term intake of high-fat, high-energy foods, sedentary exercise, etc. are all causes of obesity. For obesity, many methods of medicine and surgery have been developed, but adverse reactions and side effects are most of them, so healthier and safer non-drug treatments are being proposed.
For example, CN115067514a discloses the application of purple rice leaf in preparing health care food and/or health care product for relieving obesity, wherein the purple rice leaf is rich in dietary fiber, anthocyanin, alfalfa extract and other active ingredients, and can effectively control the weight of obese patients caused by high-fat diet, reduce fat accumulation capacity of adipose tissue and liver, thereby reducing the incidence risk of diseases caused by obesity. In addition, the use of probiotics to alleviate obesity is also a healthier and safer way, CN110684701a discloses a preservative number of CCTCC NO: the application of the lactobacillus plantarum S58 of M2019595 in the preparation of health products, foods, medicines and other products for relieving obesity not only expands the application range of the lactobacillus plantarum S58 and improves the utilization value of the lactobacillus plantarum S58, but also brings new hopes for treating obesity; CN116004472a discloses clostridium butyricum for relieving obesity and application thereof, clostridium butyricum CCFM1299 has been deposited in the microorganism strain collection in guangdong province at 2023, month 08, with the deposit number of GDMCC No:63125, after clostridium butyricum CCFM1299 is used for treating obese mice, the obesity of the mice can be relieved remarkably.
However, the probiotic preparations for relieving obesity in the prior art are limited, and the effect of relieving obesity of the preparations is still required to be further improved. Therefore, how to provide a probiotic preparation with good effect of alleviating or treating obesity, and without causing adverse reaction to patients during treatment, has become a problem to be solved urgently by those skilled in the art.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide bifidobacterium longum subspecies longum for relieving obesity and application thereof, in particular to a bifidobacterium subspecies longum Bifidobacterium longum subsp.longum BL36 strain, a culture containing the bifidobacterium subspecies longum BL36 strain, a probiotic containing the bifidobacterium subspecies longum BL36 strain and application of the bifidobacterium subspecies longum subspecies in preparation of products for preventing, relieving or treating obesity.
In order to achieve the aim of the invention, the invention adopts the following technical scheme:
in a first aspect, the present invention provides a bifidobacterium longum subspecies longum for alleviating obesity, which is named as a bifidobacterium subspecies longum Bifidobacterium longum subsp. Longum BL36 strain, and has a preservation number of CGMCC No.24413 and a preservation date of 2022, 02 and 21 days.
The invention separates and stores a new bifidobacterium longum subspecies capable of relieving obesity from faeces samples of breast-fed healthy infants, and names the bifidobacterium subspecies Bifidobacterium longum subsp.longum BL36 strain which has good gastrointestinal tract environmental tolerance capability, pathogenic bacteria inhibiting capability and cell adhesion capability, can relieve obesity, reduce blood lipid level, reduce organ index and reduce triglyceride level in liver. Therefore, the bifidobacterium longum subsp Bifidobacterium longum subsp.longum BL36 strain can be used for preparing products with the effects of preventing, relieving or treating obesity. BL36 strain is used as probiotics, and the safety is high, and drug resistance is not easy to generate.
The screening steps of the bifidobacterium longum subspecies longum BL36 strain related to the invention are as follows:
(1) Selecting a healthy breast-feeding healthy infant faeces sample, performing 10-time gradient dilution with physiological saline with the mass concentration of 0.9%, diluting for 3 times, coating on an MRS solid culture medium (medicines are purchased from Haibo organisms), culturing for 48 hours at 37 ℃, picking out bacterial colonies with different forms, then streaking and purifying on the surface of the MRS solid culture medium, picking out single colonies, performing expanded culture at 37 ℃ by using the MRS liquid culture medium, and then preserving by using glycerol with the mass concentration of 30%.
(2) And (3) carrying out in-vitro physiological characteristic test on the preserved single bacteria, screening out a single strain with the best gastrointestinal fluid tolerance (artificial simulation), HT-29 cell adhesion capability and bacteriostasis capability, and identifying and preserving the single strain.
In a second aspect, the present invention provides a culture of bifidobacterium longum subspecies longum for alleviating obesity, the method of preparation of said culture comprising: inoculating the bifidobacterium longum subspecies Bifidobacterium longum subsp.longum BL36 strain of the first aspect into a culture medium, and culturing at 30-40 ℃ (e.g. 30 ℃, 32 ℃, 35 ℃, 36 ℃,37 ℃, 38 ℃ and the like) for 18-42 hours (e.g. 18h, 19h, 20h, 21h, 22h, 23h, 24h, 30h, 36h, 40h, 42h and the like).
Other specific point values within the above numerical ranges are all selectable, and will not be described in detail herein.
The culture medium may be an MRS culture medium, and the formulation of the culture medium includes: peptone, beef extract, glucose, sodium acetate, yeast powder, diammonium hydrogen citrate, K 2 PO 4 ·3H 2 O、MgSO 4 ·7H 2 O、MnSO 4 L-cysteine, tween 80.
In a third aspect, the present invention provides a probiotic with the prevention, alleviation or treatment of obesity, the strains in said probiotic comprising the bifidobacterium longum subsp. Bifidobacterium longum subsp.longum BL36 strain of the first aspect.
The bifidobacterium longum subspecies Bifidobacterium longum subsp.longum BL36 strain related to the invention can be singly applied to related products or can be combined with other strains to be applied to the related products.
Preferably, the viable count of the bifidobacterium longum subspecies Bifidobacterium longum subsp.longum BL36 strain in the probiotics is not less than 1 multiplied by 10 9 CFU/mL or 1X 10 9 CFU/g, e.g. 1X 10 9 CFU/mL(CFU/g)、2×10 9 CFU/mL(CFU/g)、5×10 9 CFU/mL(CFU/g)、8×10 9 CFU/mL(CFU/g)、1×10 10 CFU/mL(CFU/g)、5×10 10 CFU/mL(CFU/g)、1×10 11 CFU/mL (CFU/g), etc., other specific values within the numerical range may be selected, and will not be described in detail herein.
Preferably, the strain in the probiotic agent further comprises lactobacillus casei Lactobacillus casei LC strain; the preservation number of the lactobacillus casei Lactobacillus casei LC strain is CGMCC No.15409, and the preservation date is 2018, 03 and 05.
The invention also creatively discovers that the BL36 strain can be used for preventing, relieving or treating obesity by being compounded with the lactobacillus casei Lactobacillus casei LC strain, has an effect remarkably superior to that of a single microbial inoculum or other compound formulas, and shows that the BL36 strain and the LC89 strain have a synergistic effect on the effects.
Preferably, the ratio of viable bacteria of the bifidobacterium longum subspecies Bifidobacterium longum subsp.longum BL36 strain to the lactobacillus casei Lactobacillus casei LC strain is 1:3-3:1, for example, 1:3, 1:2, 1:1, 2:1, 3:1, etc., and other specific values within the numerical range are selectable, which will not be described in detail herein.
Based on the potential interaction between BL36 strain and LC89 strain, the two strains have better synergistic effect when meeting the specific mass ratio relationship.
Preferably, the formulation of the probiotic agent comprises powder, capsule, tablet or granule.
Preferably, the probiotic agent further comprises a protective agent.
The protective agent is selected from one or a combination of at least two of skim milk, gelatin, dextrin, acacia, dextran, sodium alginate, polyvinylpyrrolidone, sucrose, lactose, trehalose, sorbitol or xylitol.
Preferably, the probiotic agent further comprises a prebiotic.
The prebiotic is selected from any one or a combination of at least two of fructo-oligosaccharide, galacto-oligosaccharide, xylo-oligosaccharide, isomalto-oligosaccharide, soy oligosaccharide, inulin, spirulina, arthrospira, coriolus versicolor polysaccharide, stachyose, polydextrose, alpha-lactalbumin or lactoferrin.
In a fourth aspect, the present invention provides the use of a long subspecies of bifidobacterium longum, or a culture as described in the second aspect, or a probiotic as described in the third aspect, in the manufacture of a product for the prevention, alleviation or treatment of obesity.
In a fifth aspect, the present invention provides the use of a long subspecies of bifidobacterium longum, or a culture, or a probiotic as described in the third aspect, in the manufacture of a product for reducing blood lipid levels.
In a sixth aspect, the present invention provides the use of a long subspecies of bifidobacterium longum, or a culture as described in the second aspect, or a probiotic as described in the third aspect, in the manufacture of a product for reducing liver index.
Compared with the prior art, the invention has the following beneficial effects:
the invention separates and stores a new bifidobacterium longum subspecies capable of relieving obesity from faeces samples of breast-fed healthy infants, and names the bifidobacterium subspecies Bifidobacterium longum subsp.longum BL36 strain which has good gastrointestinal tract environmental tolerance capability, pathogenic bacteria inhibiting capability and cell adhesion capability, can relieve obesity, reduce blood lipid level, reduce organ index and reduce triglyceride level in liver. Therefore, the bifidobacterium longum subsp Bifidobacterium longum subsp.longum BL36 strain can be used for preparing products with the effects of preventing, relieving or treating obesity. BL36 strain is used as probiotics, and the safety is high, and drug resistance is not easy to generate.
Detailed Description
In order to further describe the technical means adopted by the present invention and the effects thereof, the following describes the technical scheme of the present invention in combination with the preferred embodiments of the present invention, but the present invention is not limited to the scope of the embodiments.
The bifidobacterium longum subspecies Bifidobacterium longum subsp.longum BL36 strain is preserved in China general microbiological culture Collection center (CGMCC) No.24413, the preservation date is 2022, 02 month and 21 days, and the preservation address is North Chen Xiu No.1, 3 of the Korean region of Beijing city.
The lactobacillus casei Lactobacillus casei LC strain involved in the following is preserved in China general microbiological culture Collection center (CGMCC) with the preservation number of CGMCC No.15409 and the preservation date of 2018, 03 and 05 days, and the preservation address of the lactobacillus casei Lactobacillus casei LC strain is North Chen West Lu No.1, 3 in the Chaoyang area of Beijing city.
MRS solid medium used as follows: weighing 10g of peptone, 10g of beef extract, 20g of glucose, 2g of sodium acetate, 5g of yeast powder, 2g of diammonium hydrogen citrate and K 2 PO 4 ·3H 2 O 2.6g、MgSO 4 ·7H 2 O 0.1g、MnSO 4 0.05g, 20g of agar and 0.5g of L-cysteine are dissolved by deionized water, 1mL of Tween 80 is added, the volume is fixed to 1L, and after sterilization and cooling, the mixture is poured into a sterilized culture dish for standby.
MRS liquid medium used as follows: weighing 10g of peptone, 10g of beef extract, 20g of glucose, 2g of sodium acetate, 5g of yeast powder, 2g of diammonium hydrogen citrate and K 2 PO 4 ·3H 2 O 2.6g、MgSO 4 ·7H 2 O 0.1g、MnSO 4 0.05g and L-cysteine 0.5g, dissolved in deionized water, and addedAdding 1mL of Tween 80, fixing volume to 1L, sterilizing, and cooling.
The preparation method of the bacterial suspension comprises the following steps: inoculating the required strain into MRS liquid culture medium, culturing at 37deg.C for 24 hr for activation, and continuously activating for 2 times to obtain activating solution; inoculating the activating solution into MRS liquid culture medium according to the inoculum size of 2% (v/v), and culturing at 37 ℃ for 24 hours to obtain bacterial solution; centrifuging the bacterial liquid at 8000g for 10min, and re-suspending the bacterial body by using PBS.
Example 1
The method for screening the bifidobacterium longum subspecies for relieving obesity comprises the following steps:
(1) Selecting a healthy breast-feeding healthy infant faeces sample, performing 10-time gradient dilution with physiological saline with the mass concentration of 0.9%, diluting for 3 times, coating on an MRS solid culture medium (medicines are purchased from Haibo organisms), culturing for 48 hours at 37 ℃, picking out bacterial colonies with different forms, then streaking and purifying on the surface of the MRS solid culture medium, picking out single colonies, performing expanded culture at 37 ℃ by using the MRS liquid culture medium, and then preserving by using glycerol with the mass concentration of 30%.
(2) In vitro physiological characteristic test is carried out on a plurality of preserved single strains, and a single strain with the best gastrointestinal fluid tolerance (artificial simulation), HT-29 cell adhesion capability and bacteriostasis capability is screened out, which comprises the following specific steps:
(2.1) evaluation of environmental resistance of strains to gastrointestinal tract:
gastric juice is simulated manually: preparing 0.5% NaCl solution, adding 0.3% pepsin, adjusting pH to 2.5 with 1mol/L HCl, dissolving completely, and filtering with 0.22 μm microporous membrane for sterilization.
Manually simulating intestinal juice: preparing 0.5% NaCl solution, adding 0.1% trypsin, adjusting pH to 8.0 with 0.1mol/L NaOH, dissolving completely, and filtering with 0.22 μm microporous membrane for sterilization.
And (3) carrying out activation culture on all the preserved strains for 2 generations under anaerobic conditions, centrifuging the activated bacterial liquid, and collecting bacterial bodies. And respectively taking 0.4mL of thallus suspension, respectively inoculating 1.6mL of prepared simulated artificial gastric fluid with pH of 2.5 and simulated artificial intestinal fluid with pH of 8.0, uniformly mixing, digesting at 37 ℃, respectively taking the digestive juice of 0h and 3h to detect the number of viable bacteria, and calculating the survival rate. Wherein, the survival rate (%) =b/a×100% of the strain, wherein a represents the number of viable bacteria (CFU/mL) of the strain for 0h, and B represents the number of viable bacteria (CFU/mL) of the strain for 3 h. Each experiment was performed in 3 replicates.
(2.2) evaluation of adhesion ability of Strain to HT-29 cells:
adjusting the concentration of digested HT-29 cells to 10 5 cell/mL, 1mL per well, inoculated into a 12-well cell culture plate, at 5% CO 2 Incubating in a concentration incubator until cells grow to a monolayer, washing twice with sterile PBS, digesting one well with pancreatin, and counting cells with a blood cell counting plate; 1mL of each bacterial suspension is added into other holes respectively, and the concentration of CO is 5% 2 After incubation for 2h at 37 ℃ in an incubator, washing cells with sterile PBS for 5 times, removing non-adhered bacterial suspension, adding 0.2mL of pancreatin-EDTA buffer solution into each hole to digest the cells for 5min, adding 0.8mL of PBS after digestion, blowing evenly, and taking bacterial liquid for dilution and living bacterial counting. Since lactobacillus rhamnosus LGG is a commercial strain with better adhesion accepted in the industry, each experiment was performed in 3 replicates with it as a control strain.
(2.3) evaluation of the ability of the Strain to inhibit pathogenic bacteria:
the antagonism of the strain against the common pathogenic bacteria escherichia coli, salmonella and staphylococcus aureus was examined. The antagonistic strain is inoculated into an anaerobic glass tube of MRS liquid culture medium according to 2% (V/V) by adopting an oxford cup method, and is subjected to stationary culture at a constant temperature of 37 ℃ for 12 hours. Pathogenic strains such as escherichia coli, salmonella and staphylococcus aureus are respectively inoculated into a liquid beef extract peptone culture medium, cultured overnight at 37 ℃ with a constant temperature of 250rpm in a shaking table, and then pathogenic bacteria suspension is prepared. Cooling MRS solid culture medium to about 55deg.C, mixing with pathogenic bacteria suspension at a certain ratio to make the number of viable bacteria of the system be 10 6 CFU/mL, then rapidly pouring the culture medium into a flat plate in which an oxford cup is placed in advance, taking out the oxford cup after the culture medium is cooled and solidified, injecting 200 mu L of antagonistic strain bacteria liquid into each hole, lightly covering the flat plate, then placing the flat plate in a constant temperature incubator at 37 ℃, observing after culturing, and measuring the diameter of a bacteriostasis ring by using a vernier caliper. Each experiment was performed in 3 replicates.
Example 2
In this example, the strains obtained by screening in example 1 were subjected to physiological and biochemical characterization and 16S rRNA molecular biology identification as follows:
(1) The physiological and biochemical characteristics are shown in table 1 below:
TABLE 1
(2) 16S rRNA molecular biology identification:
taking out the strain preserved at-80 deg.C, inoculating into a centrifuge tube filled with 20mL MRS liquid culture medium according to 2% ratio, culturing at 37 deg.C for 18h, centrifuging at 8000rpm for 10min, removing supernatant, and collecting bacterial suspension. Extracting genome of the strain, adding bacterial universal primer for PCR amplification, and delivering the amplified product to China academy of sciences microbiological study for sequencing and identification.
The strain is subjected to sequencing analysis, and the 16S rRNA gene sequence and the tuf gene sequence of the strain are respectively shown as SEQ ID No.1 and SEQ ID No. 2.
SEQ ID No:1：
AGGGACCTAAGCGCCTCACTTAGACGGCTCCATCCCACAAGGGGTTAGGCCACCGGCTTCGGGTGCCCACTTTCATGACTTGACGGGCGGTCTCTACAAGGCCCGGGAACGCATTCACCGCGACGTTGCAGATTYCGCGATTACTAGCGACTCCGCCTTCACGCAGTCGAGTTGCAGACTGCGATCCGAACTGAGACCGGTTTTCAGGGATCCGCTCCGCGTCGCCGCGTCGCATCCCGTTGTACCGGCCATTGTAGCATGCGTGAAGCCCTGGACGTAAGGGGCATGATGATCTGACGTCATCCCCACCTTCCTCCGAGTTAACCCCGGCGGTCCCCCGTGAGTTCCCGGCATAATCCGCTGGCAACACGGGGCGAGGGTTGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACGACCATGCACCACCTGTGAACCCGCCCCGAAGGGAAGCCGTACTCTACGACCGTCGGGAACATGTCAAGCCCAGGTAAGGTTCTTCGCGTTGCATCGAATTAATCCGCATGCTCCGCCGCTTGTGCGGGCCCCCGTCAATTTCTTTGAGTTTTAGCCTTGCGGCCGTACTCCCAGGCGGGATGCTTAACGCGTTAGCTCCGACACGGAACCCGTGGAACGGGCCCCACATCCAGCATCCACCGTTTACGGCGTGGACTACCAGGGTATCTAATCCTGTTCGCTCCCCACGCTTTCGCTCCTCAGCGTCAGTAACGGCCCAGAGACCTGCCTTCGCCATTGGTGTTCTTCCCGATATCTACACATTCCACCGTTACACCGGGAATTCCAGTCTCCCCTACCGCACTCAAGCCCGCCCGTACCCGGCGCGGATCCACCGTTAAGCGATGGACTTTCACACCGGACGCGACGAACCGCCTACGAGCCCTTTACGCCCAATAATTCCGGATAACGCTTGCACCCTACGTATTACCGCGGCTGCTGGCACGTAGTTAGCCGGTGCTTATTCAACGGGTAAACTCACTCTCGCTTGCTCCCCGATAAAAGAGGTTTACAACCCGAAGGCCTCCATCCCTCACGCGGCGTCGCTGCATCAGGCTTGCGCCCATTGTGCAATATTCCCCACTGCCTCCCGTAGGAGTCTGGGCCCGTATCTCAGTCCCAATGTGGCCGGTCGCCCTCTCAGGCCGGCTACCCGTCGAAGCCACGGTGGGCCGTTACCCCGCCGTCAAGCTGATAGGACGCGACCCCATCCCATACCGCGAAAGCTTTCCCAGAAGACCATGCGATCAACTGGAGCATCCGGCATTACCACCCGTTTCCAGGAGCTATTCCGGTGTATGGGGCAGGTCGGTCACAGCATTACTCACCCGTTCGCCACTCTCACCACCAAGCAAGCTTGATGGATCCCGTTCGACTGCATGTGTAAGCACCCTGCGGCCTC。
SEQ ID No:2：
TCAGGCCTTCCTCCATAGCGATGGGCTGAATCAGCTCAACGGTGAAGGTAGCGTGGTCGCCCGGCTGAACCATCTCGACGCCTTCCGGCAGCTCGATGACGCCGGTGACGTCGGTGGTGCGGAAGTAGAACTGCGGACGGTAGTTGGAGAAGAACGGCGAGTGACGGCCGCCTTCGTCCTTGGTCAGCACGTAGACTTCGCCCTCGAACTTGGTGTGCGGGGTGACGGAGCCCGGCTTGGCCACAACCTGGCCACGCTCGACATCGTCACGGCCGAGACCACGCAGAAGCAGACCGGTGTTGTCGCCAGCCTCGCAGGCGTCCATGGTCTTGTGGAAGGTCTCGATGGAGGTGACGGTGGTCTGCTGGGTCGGACGGATACCAACGATCTCGACCGGGGTGTTGACGGCCAGCTGGCCACGCTCGACACGACCGGTGACAACGGTACCACGGCCGGAGATGGTGAAGACGTCCTCGATCGGCATCAGGAACGGCTTGTCCAGGTCGTGAACCGGGGTCGGGATGTAGTCGTCGACAGCGTCCATGAGGTCCTTAACGGACTGGACCCACTTCTCGTGGTCCGGAGCGTCGTCGTGCAGAGCACCGTAAGCGGAGGTGTGGATGACCGGGCAGTCACGGTCGAAGCCGTTCTCGTCGAGGAGGTCGCGGACCTCTTCTTCGACGAGCTCGATGAGCTCTTCATCGTCGACCATGTCGCACTTGTTCAGGGCGACGAGGATCTTCGGAACGCCAACCTGACGGGCGAGCAGCACGTGCTCGCGAGTCTGGGCCATCGGGCCGTCGGTGGCGGGCCACAACGAGGATAGCGCCATCCATCTGGGCAGCACCGGTAATCATGTTCTTCACGAAGTCGGCGTGGCCCGGGCAGTCGACGTGAGCGTAGTGACGCTTCTCGGTCTGGTACTCGATGTGGGCGATGTTGATGGTGA。
The sequences obtained by sequencing were analyzed with reference to the "Bojie's system bacteriology handbook" and International Journal of Systematic and Evolutionary Microbiology related research papers, and the results showed that the strain was indeed Bifidobacterium longum subsp.
Example 3
In this example, the culture conditions of bifidobacterium longum subspecies longum BL36 were optimized as follows:
inoculating Bifidobacterium longum subspecies BL36 into MRS liquid culture medium, respectively culturing at different temperatures of 20-45deg.C for 48 hr, and measuring OD600 value of the culture solution by enzyme-labeling instrument at intervals during culturing, and the results are shown in Table 2.
TABLE 2
The result shows that the bifidobacterium longum subspecies BL36 grows optimally at 30-40 ℃, and the growth stability period can be reached after 24-42h of culture.
Example 4
This example demonstrates the effect of bifidobacterium longum subspecies longum BL36 on body weight, lees coefficient and body fat rate of obese mice, as follows:
(1) Test animals: the SPF-class male mice are selected to be 56, the day-old mice are 21-28d, the weight is 22+ -2 g, and the animal house (room temperature: 22-25 ℃, humidity: 40-60%, illumination 10+ -0.5 h) is adaptively fed with common feed for one week (free diet and drinking water).
(2) Grouping: after adaptive feeding, mice were randomly divided into 7 groups: blank (Control), model (Model), BL36, LC89, BL36 and LC89 combined (combination 1), ATCC55813 and LC89 combined (combination 2), BL36 and ATCC393 combined (combination 3), 8/group.
(3) Feeding: the blank group was given normal feed and the other groups were given high fat feed for feeding (both feeds were from the same company). The water and litter were changed twice a week, and the high fat diet was changed daily to avoid fat oxidation that would give the odor impression that the mice eat.
(4) Gastric lavage: the mice in both the blank and model groups were perfused with 0.2mL of sterile physiological saline daily for 8 weeks. BL36 mice were perfused with 0.2mL of 1X 10 per day 10 CFU/mL long doubleThe bifidobacterium subspecies longum BL36 bacterial liquid lasts for 8 weeks. LC89 group mice were perfused daily with 0.2mL of 1X 10 10 CFU/mL of Lactobacillus casei LC89 broth was maintained for 8 weeks. Mice from the BL36 and LC89 combination group were gavaged daily at a concentration of 0.1mL of 1X 10 10 CFU/mL of Bifidobacterium longum subspecies longum BL36 and 0.1mL concentration were 1X 10 10 CFU/mL of the mixed bacteria solution of the cheese bacillus LC89 was continued for 8 weeks. The 0.1mL daily gavage concentration of ATCC55813 and LC89 combination was 1X 10 10 CFU/mL ATCC55813 and 0.1mL concentration is 1X 10 10 CFU/mL of the mixed bacteria solution of the cheese bacillus LC89 was continued for 8 weeks. BL36 and ATCC393 combination groups were 1X 10 at a daily gavage of 0.1mL 10 CFU/mL of Bifidobacterium longum subspecies longum BL36 and 0.1mL concentration were 1X 10 10 CFU/mL ATCC393 mixed liquor was continued for 8 weeks.
(5) The mice were fed for 8 weeks, the feeding condition of the mice was recorded every week, the body weight of the mice and the body length (distance from the tip of the nose to the anus) of the mice were measured, and the Lees coefficient was calculated; the epididymal and perirenal adipose tissues were removed, and the body fat rate was measured and calculated according to the following calculation formula.
The weekly changes in body weight of the mice are shown in Table 3.
TABLE 3 Table 3
The results of weight gain, lees coefficient, body fat rate after 8 weeks for each group of mice are shown in table 4.
TABLE 4 Table 4
From the results in tables 3 and 4, the mice in the model group had the most weight gain, which was significantly higher than the other groups; the weight gain of mice in combination with group 1 was minimal in the five intervention groups. The Lees coefficient is a value reflecting the degree of obesity in humans or animals, with a larger value indicating a higher degree of obesity in individuals. The Lees coefficient value of the model group is the largest in all test groups, which indicates that the mice are obese; this was substantially consistent with the weight gain of the mice during the trial; the mice in the five intervention groups had less Lees coefficients than the model group. In addition to observing the body weight and Lees coefficient of mice, body fat rate is also an important indicator for measuring the obesity degree of mice. The body fat rate of mice in the model group is highest, the body fat rate of mice in other groups is lower than that of mice in the model group, and the body fat rate of mice in the combined 1 group in the five intervention groups is lowest. Taken together, the BL36 strain according to the present invention was found to be very effective in alleviating obesity in mice based on the data of weight gain, lees coefficient and body fat rate in mice.
Example 5
This example demonstrates the effect of bifidobacterium longum subspecies longum BL36 on blood lipid levels in obese mice, as follows:
example 4 mice were perfused with blood for 8 weeks, whole blood was obtained by eye blood collection, standing at 20 ℃ for 2 hours, at 4 ℃ for 3000r/min, centrifuging for 10min, and the supernatant serum was collected to measure the concentrations of Total Cholesterol (TC), triglyceride (TG), low Density Lipoprotein (LDL) and High Density Lipoprotein (HDL) in the serum of the mice. The four blood lipid kits produced by Nanjing's established bioengineering study were used for measurement, and the results are shown in Table 5 below:
TABLE 5
As can be seen from the data in table 5, the mice were on a high-fat diet for a long period of time, resulting in excessive fatty acid production in the body, thereby promoting the increase of TG and TC contents in serum; if the mice are obese for a long period of time, in vivo lipase accelerates the treatment, resulting in a decrease in HDL content and an increase in LDL content. The data in the above table show that the TG, TC and LDL levels in the mice in the model group are all significantly increased, while the HDL levels are significantly reduced, compared to the control group; the five intervention groups all improved to different degrees, the effect of the combined 1 group was more obvious compared with the LC89 and BL36 groups, and the effect was more similar to that of the control group. The results show that the BL36 strain can remarkably improve the blood lipid rise caused by high-fat diet.
Example 6
This example demonstrates the effect of bifidobacterium longum subspecies longum BL36 on organ index in obese mice, as follows:
example 4 after 8 weeks of gastric lavage, the heart, kidney, liver and spleen of the mice were removed after blood was taken out from the eyeballs, washed with sterile physiological saline, dried by suction with filter paper, weighed, and the organ index was measured, and calculated according to the following formula. The results are shown in Table 6 below.
TABLE 6
As can be seen from the data in Table 6, the growth status of mice can be reflected by organ indexes. Long-term eating of high-fat diet can cause fat cavity in the liver of the mice and increase liver quality. The data in the above table show that liver index is obviously increased due to the ingestion of high-fat feed by mice; while the other intervention groups had significantly reduced organ index compared to the model group.
Example 7
This example demonstrates the effect of bifidobacterium longum subspecies longum BL36 on Triglycerides (TG) in the liver of obese mice, as follows:
example 6 mouse livers were taken out, 0.1g was weighed, sterile physiological saline was added in a ratio of 1:9, grinding was performed under ice bath conditions, at 4 ℃ and 4000r/min, centrifugation was performed for 10min, the supernatant was taken out and placed in a new EP tube, and the measurement was performed using a triglyceride kit produced by the institute of bioengineering, built in tokyo, and the measurement results were shown in table 7 below.
TABLE 7
The liver is an important place for synthesizing triglyceride, and when the triglyceride is excessively synthesized, the triglyceride cannot be transported in time and is accumulated in the liver. From the data in Table 7, it can be seen that the mice eat high-fat feed for a long period of time, and the accumulation of TG in the liver of the mice in the model group is significantly greater than that in the blank group and other intervention groups.
The applicant states that the present invention is illustrated by the above examples as a bifidobacterium longum subspecies longum for alleviating obesity and its use, but the present invention is not limited to, i.e. it is not meant that the present invention must be practiced in dependence upon, the above examples. It should be apparent to those skilled in the art that any modification of the present invention, equivalent substitution of raw materials for the product of the present invention, addition of auxiliary components, selection of specific modes, etc., falls within the scope of the present invention and the scope of disclosure.
The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited to the specific details of the above embodiments, and various simple modifications can be made to the technical solution of the present invention within the scope of the technical concept of the present invention, and all the simple modifications belong to the protection scope of the present invention.
In addition, the specific features described in the above embodiments may be combined in any suitable manner, and in order to avoid unnecessary repetition, various possible combinations are not described further.
Claims (10)
1. The long bifidobacterium subspecies for relieving obesity are named as Bifidobacterium longum subsp.longum BL36 strain, the preservation number is CGMCC No.24413, and the preservation date is 2022, 02 and 21.
2. A culture of bifidobacterium longum subspecies longum for alleviating obesity, characterized in that the method of preparation of said culture comprises: inoculating the bifidobacterium longum subspecies Bifidobacterium longum subsp.longum BL36 strain in the culture medium and culturing at 30-40 ℃ for 18-42h.
3. A probiotic with the prevention, alleviation or treatment of obesity, characterized in that the strain in the probiotic comprises the bifidobacterium longum subsp. Bifidobacterium longum. Longum BL36 strain of claim 1.
4. A probiotic according to claim 3, characterized in that the viable count of the bifidobacterium longum subsp Bifidobacterium longum subsp longum BL36 strain in the probiotic is not lower than 1 x 10 9 CFU/mL or 1X 10 9 CFU/g。
5. The probiotic according to claim 3 or 4, characterized in that the strain in the probiotic further comprises lactobacillus casei Lactobacillus casei LC strain 89; the preservation number of the lactobacillus casei Lactobacillus casei LC strain is CGMCC No.15409, and the preservation date is 2018, 03 and 05.
6. The probiotic according to claim 5, characterized in that the ratio of viable count of bifidobacterium longum subsp. Bifidobacterium longum subsp.longum BL36 strain to lactobacillus casei Lactobacillus casei LC strain is 1:3-3:1.
7. The probiotic according to any one of claims 3 to 6, characterized in that the formulation of the probiotic comprises a powder, a capsule, a tablet or a granule;
preferably, the probiotic agent also contains a protective agent;
preferably, the probiotic agent further comprises a prebiotic.
8. Use of a long subspecies of bifidobacterium longum as claimed in claim 1, or a culture as claimed in claim 2, or a probiotic as claimed in any one of claims 3 to 7, in the manufacture of a product for the prevention, alleviation or treatment of obesity.
9. Use of a bifidobacterium longum subspecies longum as claimed in claim 1, or a culture as claimed in claim 2, or a probiotic as claimed in any one of claims 3 to 7, in the manufacture of a product for reducing blood lipid levels.
10. Use of a long subspecies of bifidobacterium longum as claimed in claim 1 or a culture as claimed in claim 2 or a probiotic as claimed in any one of claims 3 to 7 in the manufacture of a product to reduce liver index.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310873429.0A CN116814501B (en) | 2023-07-17 | 2023-07-17 | Bifidobacterium longum subspecies capable of relieving obesity and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310873429.0A CN116814501B (en) | 2023-07-17 | 2023-07-17 | Bifidobacterium longum subspecies capable of relieving obesity and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116814501A true CN116814501A (en) | 2023-09-29 |
| CN116814501B CN116814501B (en) | 2024-02-09 |
Family
ID=88139104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310873429.0A Active CN116814501B (en) | 2023-07-17 | 2023-07-17 | Bifidobacterium longum subspecies capable of relieving obesity and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116814501B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116077536A (en) * | 2023-03-17 | 2023-05-09 | 微康益生菌(苏州)股份有限公司 | Microecological live bacteria preparation for improving obesity-related metabolic diseases and preparation method and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103275893A (en) * | 2013-05-06 | 2013-09-04 | 哈尔滨美华生物技术股份有限公司 | Complex microbial inoculants of bifidobacterium longum and bifidobacterium animalis and preparation method of complex microbial inoculants |
| US20200345051A1 (en) * | 2017-11-24 | 2020-11-05 | University College Cork, National University Of Ireland, Cork | A composition comprising a cohort of bacteria |
| KR20210022221A (en) * | 2019-08-19 | 2021-03-03 | 주식회사 빙그레 | Bifidobacterium longum subsp. longum having both abilities of reducing total cholesterol in serum and immune regulation and its application |
| CN113234640A (en) * | 2021-06-21 | 2021-08-10 | 美益添生物医药(武汉)有限公司 | Bifidobacterium longum MF-269 and application thereof |
| CN113430133A (en) * | 2021-06-24 | 2021-09-24 | 微康益生菌(苏州)股份有限公司 | Composite probiotics capable of relieving ulcerative colitis, preparation method and application thereof |
| CN115927049A (en) * | 2022-07-20 | 2023-04-07 | 华南理工大学 | Bifidobacterium longum subspecies infantis B2-01 and application thereof |
| CN116286551A (en) * | 2023-04-25 | 2023-06-23 | 天赋能(天津)功能食品研究发展有限公司 | Application of bifidobacterium longum subspecies infantis in regulating in-vivo fat metabolism, shaping, reducing fat and improving obesity |
| CN116376740A (en) * | 2022-12-08 | 2023-07-04 | 杭州娃哈哈科技有限公司 | Bifidobacterium longum with blood sugar reducing effect and application thereof |
-
2023
- 2023-07-17 CN CN202310873429.0A patent/CN116814501B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103275893A (en) * | 2013-05-06 | 2013-09-04 | 哈尔滨美华生物技术股份有限公司 | Complex microbial inoculants of bifidobacterium longum and bifidobacterium animalis and preparation method of complex microbial inoculants |
| US20200345051A1 (en) * | 2017-11-24 | 2020-11-05 | University College Cork, National University Of Ireland, Cork | A composition comprising a cohort of bacteria |
| KR20210022221A (en) * | 2019-08-19 | 2021-03-03 | 주식회사 빙그레 | Bifidobacterium longum subsp. longum having both abilities of reducing total cholesterol in serum and immune regulation and its application |
| CN113234640A (en) * | 2021-06-21 | 2021-08-10 | 美益添生物医药(武汉)有限公司 | Bifidobacterium longum MF-269 and application thereof |
| CN113430133A (en) * | 2021-06-24 | 2021-09-24 | 微康益生菌(苏州)股份有限公司 | Composite probiotics capable of relieving ulcerative colitis, preparation method and application thereof |
| CN115927049A (en) * | 2022-07-20 | 2023-04-07 | 华南理工大学 | Bifidobacterium longum subspecies infantis B2-01 and application thereof |
| CN116376740A (en) * | 2022-12-08 | 2023-07-04 | 杭州娃哈哈科技有限公司 | Bifidobacterium longum with blood sugar reducing effect and application thereof |
| CN116286551A (en) * | 2023-04-25 | 2023-06-23 | 天赋能(天津)功能食品研究发展有限公司 | Application of bifidobacterium longum subspecies infantis in regulating in-vivo fat metabolism, shaping, reducing fat and improving obesity |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116077536A (en) * | 2023-03-17 | 2023-05-09 | 微康益生菌(苏州)股份有限公司 | Microecological live bacteria preparation for improving obesity-related metabolic diseases and preparation method and application thereof |
| CN116077536B (en) * | 2023-03-17 | 2023-11-28 | 微康益生菌(苏州)股份有限公司 | Microecological live bacteria preparation for improving obesity-related metabolic diseases and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116814501B (en) | 2024-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111254089B (en) | Lactobacillus plantarum with weight losing function and application thereof | |
| CN110122877B (en) | Lactobacillus rhamnosus and application thereof | |
| CN109182207B (en) | Lactobacillus acidophilus La-SJLH001 with probiotic functions of regulating blood sugar level, cholesterol level and the like and application thereof | |
| CN110272842A (en) | One plant of lactobacillus plantarum LP104 with fat reducing and weight reducing function | |
| CN111254090B (en) | Lactobacillus reuteri with weight losing function and application thereof | |
| CN111925961B (en) | Lactobacillus plantarum Lp2 and application thereof | |
| CN111213885A (en) | Probiotic composition with blood fat regulating effect and preparation method and application thereof | |
| CN110564638A (en) | Lactobacillus reuteri with probiotic characteristics and application thereof | |
| CN110106119A (en) | The Lactobacillus rhamnosus M9 of one plant of isolated from mother's milk and its application | |
| CN114574406B (en) | Lactobacillus rhamnosus strain WKA55, and application and product thereof in preparation of product for preventing and treating alcoholic liver injury | |
| CN116814501B (en) | Bifidobacterium longum subspecies capable of relieving obesity and application thereof | |
| CN110959867A (en) | Composite probiotic microcapsule powder for emulsification and preparation method and application thereof | |
| CN111387506A (en) | Application of lactobacillus acidophilus and composition containing lactobacillus acidophilus | |
| CN116083324A (en) | Bifidobacterium animalis subspecies BA79 capable of improving or treating irritable bowel syndrome and culture method and application thereof | |
| CN114437989B (en) | Lactobacillus fermentum LF028 with blood sugar reducing effect and application thereof | |
| JP4280016B2 (en) | Diabetes complications prevention, improvement, treatment | |
| CN114214230A (en) | Lactobacillus North having ability of copolymerizing helicobacter pylori and application thereof | |
| CN111685255B (en) | Probiotic solid beverage for enhancing immune function and preparation method thereof | |
| CN116445356B (en) | Bifidobacterium animalis subspecies BA67 for regulating intestinal flora and enhancing immunity and application thereof | |
| JPH0696537B2 (en) | Serum cholesterol elevation inhibitor | |
| CN115895966B (en) | Bifidobacterium bifidum BL002 for assisting in relieving gout and application thereof | |
| CN116445360A (en) | Lactobacillus rhamnosus with effect of relieving chronic alcoholic liver injury and application thereof | |
| CN117603828A (en) | Lactobacillus rhamnosus LRa66 with blood glucose and blood lipid reducing functions and application thereof | |
| CN114921383A (en) | Probiotic preparation with cholesterol removing function and preparation method thereof | |
| CN114717219A (en) | Lactobacillus reuteri preparation with functions of resisting oxidation and reducing cholesterol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |